- Merck & Co Inc MRK is reportedly mulling buying cancer-focused biotech Seagen Inc SGEN, Wall Street Journal reported citing people familiar with the matter.
- If the deal happens, it would be significant, given Seagen's market value of roughly $28 billion.
- According to the report, some people said other unnamed suitors are also eying Seagen, a perennially speculated takeover target.
- Also Read: Amid Domestic Violence Allegation, Longtime Seagen CEO Takes Leave of Absence.
- Talks have been underway for a while, the people said.
- Though the people cautioned that pulling off the deal could be tricky given the heightened risk of a regulatory challenge.
- WSJ also mentioned that a marketing agreement is also possible between Merck and Seagen.
- Related: Read Why This Analyst Is 'Encouraged' By Seagen's Q1 Sales.
- Price Action: SGEN shares are up 13.30% at $166.26, and MRK stock is up 0.06% at $84.94 during the market session on the last check Friday.
- Photo via Pixabay
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
